VIB VERMOEGEN AG (VIH1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:VIH1 • DE000A2YPDD0

9.84 EUR
0 (0%)
Last: Feb 5, 2026, 05:28 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to VIH1. VIH1 was compared to 66 industry peers in the Real Estate Management & Development industry. There are concerns on the financial health of VIH1 while its profitability can be described as average. VIH1 may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • VIH1 had positive earnings in the past year.
  • In the past year VIH1 had a positive cash flow from operations.
  • In the past 5 years VIH1 has always been profitable.
  • In the past 5 years VIH1 always reported a positive cash flow from operatings.
VIH1.DE Yearly Net Income VS EBIT VS OCF VS FCFVIH1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

  • With a Return On Assets value of 1.69%, VIH1 perfoms like the industry average, outperforming 57.58% of the companies in the same industry.
  • VIH1 has a Return On Equity (3.99%) which is in line with its industry peers.
  • With a decent Return On Invested Capital value of 3.21%, VIH1 is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • VIH1 had an Average Return On Invested Capital over the past 3 years of 4.05%. This is in line with the industry average of 3.94%.
Industry RankSector Rank
ROA 1.69%
ROE 3.99%
ROIC 3.21%
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
VIH1.DE Yearly ROA, ROE, ROICVIH1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • With a decent Profit Margin value of 34.63%, VIH1 is doing good in the industry, outperforming 74.24% of the companies in the same industry.
  • In the last couple of years the Profit Margin of VIH1 has declined.
  • VIH1's Operating Margin of 70.15% is amongst the best of the industry. VIH1 outperforms 89.39% of its industry peers.
  • VIH1's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 78.88%, VIH1 is in the better half of the industry, outperforming 68.18% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VIH1 has remained more or less at the same level.
Industry RankSector Rank
OM 70.15%
PM (TTM) 34.63%
GM 78.88%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
VIH1.DE Yearly Profit, Operating, Gross MarginsVIH1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • VIH1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, VIH1 has about the same amount of shares outstanding.
  • The number of shares outstanding for VIH1 has been increased compared to 5 years ago.
  • VIH1 has a better debt/assets ratio than last year.
VIH1.DE Yearly Shares OutstandingVIH1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
VIH1.DE Yearly Total Debt VS Total AssetsVIH1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • VIH1 has an Altman-Z score of 0.70. This is a bad value and indicates that VIH1 is not financially healthy and even has some risk of bankruptcy.
  • VIH1 has a worse Altman-Z score (0.70) than 62.12% of its industry peers.
  • The Debt to FCF ratio of VIH1 is 10.39, which is on the high side as it means it would take VIH1, 10.39 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 10.39, VIH1 is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
  • VIH1 has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
  • VIH1's Debt to Equity ratio of 1.01 is in line compared to the rest of the industry. VIH1 outperforms 45.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 10.39
Altman-Z 0.7
ROIC/WACC0.73
WACC4.41%
VIH1.DE Yearly LT Debt VS Equity VS FCFVIH1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 1.03 indicates that VIH1 should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.03, VIH1 is in line with its industry, outperforming 43.94% of the companies in the same industry.
  • A Quick Ratio of 1.03 indicates that VIH1 should not have too much problems paying its short term obligations.
  • VIH1's Quick ratio of 1.03 is fine compared to the rest of the industry. VIH1 outperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
VIH1.DE Yearly Current Assets VS Current LiabilitesVIH1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • VIH1 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.11%.
  • Measured over the past years, VIH1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.74% on average per year.
  • Looking at the last year, VIH1 shows a small growth in Revenue. The Revenue has grown by 4.50% in the last year.
  • Measured over the past years, VIH1 shows a small growth in Revenue. The Revenue has been growing by 2.78% on average per year.
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%

3.2 Future

  • VIH1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.54% yearly.
  • The Revenue is expected to grow by 10.81% on average over the next years. This is quite good.
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIH1.DE Yearly Revenue VS EstimatesVIH1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VIH1.DE Yearly EPS VS EstimatesVIH1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.03, the valuation of VIH1 can be described as very reasonable.
  • Based on the Price/Earnings ratio, VIH1 is valued cheaper than 81.82% of the companies in the same industry.
  • VIH1 is valuated cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 4.51 indicates a rather cheap valuation of VIH1.
  • Based on the Price/Forward Earnings ratio, VIH1 is valued cheaply inside the industry as 96.97% of the companies are valued more expensively.
  • VIH1's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.20.
Industry RankSector Rank
PE 9.03
Fwd PE 4.51
VIH1.DE Price Earnings VS Forward Price EarningsVIH1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VIH1 indicates a rather cheap valuation: VIH1 is cheaper than 95.45% of the companies listed in the same industry.
  • 89.39% of the companies in the same industry are more expensive than VIH1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.27
EV/EBITDA 6.28
VIH1.DE Per share dataVIH1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • VIH1 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.86
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

1

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.41%, VIH1 is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 4.55, VIH1 has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, VIH1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.41%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
VIH1.DE Yearly Dividends per shareVIH1.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2024 2025 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y11.54%
EPS Next 3YN/A
VIH1.DE Yearly Income VS Free CF VS DividendVIH1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

More info and screens

Find the best dividend stocksShow peers with best dividend

VIB VERMOEGEN AG

FRA:VIH1 (2/5/2026, 5:28:00 PM)

9.84

0 (0%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)08-27
Earnings (Next)04-29
Inst Owners0.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap325.21M
Revenue(TTM)104.37M
Net Income(TTM)36.14M
Analysts82.86
Price Target11.73 (19.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.41%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 9.03
Fwd PE 4.51
P/S 3.12
P/FCF 3.27
P/OCF 3.27
P/B 0.36
P/tB 0.37
EV/EBITDA 6.28
EPS(TTM)1.09
EY11.08%
EPS(NY)2.18
Fwd EY22.18%
FCF(TTM)3.01
FCFY30.54%
OCF(TTM)3.01
OCFY30.54%
SpS3.16
BVpS27.39
TBVpS26.47
PEG (NY)0.86
PEG (5Y)N/A
Graham Number25.92
Profitability
Industry RankSector Rank
ROA 1.69%
ROE 3.99%
ROCE 3.73%
ROIC 3.21%
ROICexc 3.25%
ROICexgc 3.3%
OM 70.15%
PM (TTM) 34.63%
GM 78.88%
FCFM 95.17%
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
ROICexc(3y)4.4%
ROICexc(5y)4.63%
ROICexgc(3y)4.52%
ROICexgc(5y)4.7%
ROCE(3y)4.69%
ROCE(5y)5.03%
ROICexgc growth 3Y-10.75%
ROICexgc growth 5Y-3.98%
ROICexc growth 3Y-11.34%
ROICexc growth 5Y-4.36%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 10.39
Debt/EBITDA 4.3
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 46.63%
Profit Quality 274.83%
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z 0.7
F-Score4
WACC4.41%
ROIC/WACC0.73
Cap/Depr(3y)0.86%
Cap/Depr(5y)88.75%
Cap/Sales(3y)0.31%
Cap/Sales(5y)0.52%
Profit Quality(3y)144.88%
Profit Quality(5y)156.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.54%
EBIT growth 3Y-3.27%
EBIT growth 5Y0.72%
EBIT Next Year69.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.92%
FCF growth 3Y6.73%
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3Y6.76%
OCF growth 5Y5.7%

VIB VERMOEGEN AG / VIH1.DE FAQ

What is the fundamental rating for VIH1 stock?

ChartMill assigns a fundamental rating of 5 / 10 to VIH1.DE.


Can you provide the valuation status for VIB VERMOEGEN AG?

ChartMill assigns a valuation rating of 8 / 10 to VIB VERMOEGEN AG (VIH1.DE). This can be considered as Undervalued.


What is the profitability of VIH1 stock?

VIB VERMOEGEN AG (VIH1.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for VIH1 stock?

The financial health rating of VIB VERMOEGEN AG (VIH1.DE) is 3 / 10.